{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T07:17:00Z","timestamp":1794986220962,"version":"4.9.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Pulmonary hypertension (PH) is a complicated disease which has complex causes and poor outcome. Many factors are involved in the increase of pulmonary artery pressure. It is often difficult to identify the specific cause of a particular patient. However, identifying the etiology is of great importance for specifying treatment strategies and improving the prognosis of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 58-year-old male was admitted because of fatigue, breath shortness for 6 months, which got worse in the last 3 months. The ultrasound cardiogram (UCG) indicated a remarkably elevated pulmonary artery systolic pressure (PASP\u200a=\u200a82 mm Hg). He had hypertension for 15 years. Besides, his spleen was found to be enlarged since 15 years ago. Bone marrow biopsy of the patient revealed myeloproliferative neoplasm (MPN) with severe myelofibrosis (MF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Myeloproliferative neoplasm (MPN) with severe myelofibrosis (MF) which in turn caused PH and portal vein hypertension (PVH).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>We treated the patient with diuretics and fosinopril, and also steroids and thalidomide for his MPN\/MF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Two weeks later, the pulmonary artery pressure (PAP) was remarkably decreased (PASP\u200a=\u200a53.1 mm Hg by UCG, mean PAP\u200a=\u200a21 mm Hg by right cardiac catheterization). Within 2 years\u2019 follow-up, his circulatory state and hematological state remained stable.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>It is often difficult to define the cause of PH, but it is important for making the appropriate treatment at the same time.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014594","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T11:50:14Z","timestamp":1553169014000},"page":"e14594","source":"Crossref","is-referenced-by-count":7,"title":["Pulmonary hypertension with massive megalosplenia"],"prefix":"10.1097","volume":"98","author":[{"given":"Tieci","family":"Yi","sequence":"first","affiliation":[{"name":"Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"Qiu","sequence":"additional","affiliation":[{"name":"Medical Imaging Department, Peking University First Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/resp.13392","article-title":"Pulmonary arterial hypertension in a multi-ethnic Asian population: characteristics, survival and mortality predictors from a 14-year follow-up study","volume":"24","author":"Lim","year":"2019","journal-title":"Respirology"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1378\/chest.15-0300","article-title":"Five-year outcomes of patients enrolled in the REVEAL registry","volume":"148","author":"Farber","year":"2015","journal-title":"Chest"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.hlc.2017.08.018","article-title":"Survival of idiopathic pulmonary arterial hypertension patients in the modern era in Australia and New Zealand","volume":"27","author":"Strange","year":"2018","journal-title":"Heart Lung Circ"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","article-title":"Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era","volume":"122","author":"Humbert","year":"2010","journal-title":"Circulation"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"R6-20230914","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ccm.2013.08.010","article-title":"Epidemiology of pulmonary arterial hypertension","volume":"34","author":"Taichman","year":"2013","journal-title":"Clin Chest Med"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2174\/1389201018666170615082510","article-title":"An expanding role of biomarkers in pulmonary arterial hypertension","volume":"18","author":"Yildiz","year":"2017","journal-title":"Curr Pharm Biotechnol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0002-9343(92)90576-W","article-title":"Cardiac involvement in patients with myeloproliferative disorders","volume":"93","author":"Reisner","year":"1992","journal-title":"Am J Med"},{"key":"R11-20230914","first-page":"245","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"89","author":"Garypidou","year":"2004","journal-title":"Haematologica"},{"key":"R12-20230914","first-page":"1779","article-title":"Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"98","author":"Gupta","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/10428190701493928","article-title":"Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis","volume":"48","author":"Altintas","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.leu.2404943","article-title":"Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status","volume":"22","author":"Cortelezzi","year":"2008","journal-title":"Leukemia"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/10428194.2013.797083","article-title":"Pulmonary hypertension in patients with chronic myeloproliferative neoplasms","volume":"55","author":"Chebrek","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1183\/16000617.0041-2015","article-title":"Pulmonary hypertension in patients with chronic myeloproliferative disorders","volume":"24","author":"Adir","year":"2015","journal-title":"Eur Respir J"},{"issue":"(3 suppl)","key":"R17-20230914","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/j.bbmt.2017.12.329","article-title":"Application of noninvasive methods to detect pulmonary hypertension in pre-transplant patients with myelofibrosis","volume":"24","author":"Salit","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"R19-20230914","first-page":"89","article-title":"Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"Mughal","year":"2014","journal-title":"Int J Gen Med"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4330\/wjc.v8.i12.703","article-title":"Hematological disorders and pulmonary hypertension","volume":"8","author":"Mathew","year":"2016","journal-title":"World J Cardiol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2014.04.004","article-title":"Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension","volume":"15","author":"Yan","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R22-20230914","first-page":"845","article-title":"A clinical analysis of six cases of portal hypertension secondary to primary myelofibrosis and review of literatures","volume":"49","author":"Song","year":"2010","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajh.20388","article-title":"Myelofibrosis-associated massive splenomegaly: a cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea","volume":"80","author":"Ziakas","year":"2005","journal-title":"Am J Hematol"},{"key":"R24-20230914","first-page":"1186","article-title":"Pulmonary hypertension complicating portal hypertension: portopulmonary hypertension","volume":"59","author":"Katsuta","year":"2001","journal-title":"Nihon Rinsho"},{"key":"R25-20230914","doi-asserted-by":"crossref","DOI":"10.1177\/1179545X17695233","article-title":"Treatment of myelofibrosis: old and new strategies","volume":"10","author":"Iurlo","year":"2017","journal-title":"Clin Med Insights Blood Disord"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/1078155216670229","article-title":"Pharmacologic management of myelofibrosis","volume":"23","author":"Leung","year":"2017","journal-title":"J Oncol Pharmacy Pract"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17474086.2017.1317590","article-title":"Management of myelofibrosis: JAK inhibition and beyond","volume":"10","author":"Stahl","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.120816","article-title":"Pulmonary arterial hypertension exacerbated by ruxolitinib","volume":"100","author":"Low","year":"2015","journal-title":"Haematologica"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/15563650.2018.1447119","article-title":"Drug-associated pulmonary arterial hypertension","volume":"56","author":"McGee","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-017-0029-4","article-title":"Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response","volume":"8","author":"Luo","year":"2018","journal-title":"Blood Cancer J"},{"key":"R31-20230914","first-page":"208","article-title":"Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS)","volume":"113","author":"Belohlavek","year":"2001","journal-title":"Wiener klinische Wochenschrift"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1111\/j.1572-0241.2005.50374.x","article-title":"Portal hypertension secondary to myelofibrosis: a study of three cases","volume":"100","author":"Alvarez-Larr\u00e1n","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R33-20230914","first-page":"771","article-title":"Portal hypertension complicating myelofibrosis: reversal following splenectomy","volume":"117","author":"Lukie","year":"1977","journal-title":"Can Med Assoc J"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5320\/wjr.v5.i2.69","article-title":"Post splenectomy related pulmonary hypertension","volume":"5","author":"Palkar","year":"2015","journal-title":"World J Respirol"},{"key":"R35-20230914","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2016.157008","article-title":"Risk of cardiovascular events and pulmonary hypertension following splenectomy: a Danish population-based cohort study from 1996-2012","volume":"102","author":"R\u00f8rholt","year":"2017","journal-title":"Haematologica"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/apt.13569","article-title":"Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt","volume":"43","author":"Wannhoff","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.dld.2017.06.011","article-title":"Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis","volume":"49","author":"Busk","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"113","author":"Mesa","year":"2009","journal-title":"Blood"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tipsro.2017.08.002","article-title":"Treatment of symptomatic splenomegaly with low doses of radiotherapy: retrospective analysis and review of the literature","volume":"3","author":"de la Pinta","year":"2017","journal-title":"Tech Innovations Patient Support Radiation Oncol"},{"key":"R40-20230914","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1046\/j.1365-2141.2002.03695.x","article-title":"Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia","volume":"118","author":"Steensma","year":"2002","journal-title":"Br J Haematol"},{"key":"R41-20230914","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1086\/687291","article-title":"Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantation","volume":"6","author":"Faiz","year":"2016","journal-title":"Pulmonary Circ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903220-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:19:49Z","timestamp":1694719189000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903220-00003"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014594","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}